These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 25807301)

  • 1. The slow dissociation rate of K-1602 contributes to the enhanced inhibitory activity of this novel alkyl-aryl-bearing fluoroketolide.
    Krokidis M; Bougas A; Stavropoulou M; Kalpaxis D; Dinos GP
    J Enzyme Inhib Med Chem; 2016; 31(2):276-82. PubMed ID: 25807301
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Kinetic studies on the interaction between a ribosomal complex active in peptide bond formation and the macrolide antibiotics tylosin and erythromycin.
    Dinos GP; Kalpaxis DL
    Biochemistry; 2000 Sep; 39(38):11621-8. PubMed ID: 10995229
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dissecting the ribosomal inhibition mechanism of a new ketolide carrying an alkyl-aryl group at C-13 of its lactone ring.
    Krokidis MG; Kostopoulou ON; Kalpaxis DL; Dinos GP
    Int J Antimicrob Agents; 2010 Mar; 35(3):235-9. PubMed ID: 20045632
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Insights into the mode of action of novel fluoroketolides, potent inhibitors of bacterial protein synthesis.
    Krokidis MG; Márquez V; Wilson DN; Kalpaxis DL; Dinos GP
    Antimicrob Agents Chemother; 2014; 58(1):472-80. PubMed ID: 24189263
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Binding site of the bridged macrolides in the Escherichia coli ribosome.
    Xiong L; Korkhin Y; Mankin AS
    Antimicrob Agents Chemother; 2005 Jan; 49(1):281-8. PubMed ID: 15616307
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Distinct mode of interaction of a novel ketolide antibiotic that displays enhanced antimicrobial activity.
    Kouvela EC; Kalpaxis DL; Wilson DN; Dinos GP
    Antimicrob Agents Chemother; 2009 Apr; 53(4):1411-9. PubMed ID: 19164155
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of the ribosomal peptidyl transferase reaction by the mycarose moiety of the antibiotics carbomycin, spiramycin and tylosin.
    Poulsen SM; Kofoed C; Vester B
    J Mol Biol; 2000 Dec; 304(3):471-81. PubMed ID: 11090288
    [TBL] [Abstract][Full Text] [Related]  

  • 8. On the mechanism of action of 9-O-arylalkyloxime derivatives of 6-O-mycaminosyltylonolide, a new class of 16-membered macrolide antibiotics.
    Karahalios P; Kalpaxis DL; Fu H; Katz L; Wilson DN; Dinos GP
    Mol Pharmacol; 2006 Oct; 70(4):1271-80. PubMed ID: 16873579
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design, synthesis and antibacterial activity of novel ketolides bearing an aryltetrazolyl-substituted alkyl side chain.
    Song QL; Guo BQ; Zhang W; Lan P; Sun PH; Chen WM
    J Antibiot (Tokyo); 2011 Aug; 64(8):571-81. PubMed ID: 21772308
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ketolide antimicrobial activity persists after disruption of interactions with domain II of 23S rRNA.
    Novotny GW; Jakobsen L; Andersen NM; Poehlsgaard J; Douthwaite S
    Antimicrob Agents Chemother; 2004 Oct; 48(10):3677-83. PubMed ID: 15388419
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Binding site of macrolide antibiotics on the ribosome: new resistance mutation identifies a specific interaction of ketolides with rRNA.
    Garza-Ramos G; Xiong L; Zhong P; Mankin A
    J Bacteriol; 2001 Dec; 183(23):6898-907. PubMed ID: 11698379
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Erythromycin, Cethromycin and Solithromycin display similar binding affinities to the E. coli's ribosome: A molecular simulation study.
    Nguyen HL; An PH; Thai NQ; Linh HQ; Li MS
    J Mol Graph Model; 2019 Sep; 91():80-90. PubMed ID: 31200217
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Insights into the mechanism of azithromycin interaction with an Escherichia coli functional ribosomal complex.
    Dinos GP; Michelinaki M; Kalpaxis DL
    Mol Pharmacol; 2001 Jun; 59(6):1441-5. PubMed ID: 11353804
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Toward the rational design of macrolide antibiotics to combat resistance.
    Pavlova A; Parks JM; Oyelere AK; Gumbart JC
    Chem Biol Drug Des; 2017 Nov; 90(5):641-652. PubMed ID: 28419786
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New Fluorescent Macrolide Derivatives for Studying Interactions of Antibiotics and Their Analogs with the Ribosomal Exit Tunnel.
    Tereshchenkov AG; Shishkina AV; Karpenko VV; Chertkov VA; Konevega AL; Kasatsky PS; Bogdanov AA; Sumbatyan NV
    Biochemistry (Mosc); 2016 Oct; 81(10):1163-1172. PubMed ID: 27908240
    [TBL] [Abstract][Full Text] [Related]  

  • 16. C-9 Alkenylidine bridged macrolides: WO2008061189. Enanta Pharmaceuticals, Inc.
    Poce G; Cesare Porretta G; Biava M
    Expert Opin Ther Pat; 2009 Jun; 19(6):901-6. PubMed ID: 19473109
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Ribosomal antibiotics].
    Man'kin AS
    Mol Biol (Mosk); 2001; 35(4):597-609. PubMed ID: 11524946
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Time-resolved binding of azithromycin to Escherichia coli ribosomes.
    Petropoulos AD; Kouvela EC; Starosta AL; Wilson DN; Dinos GP; Kalpaxis DL
    J Mol Biol; 2009 Jan; 385(4):1179-92. PubMed ID: 19071138
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 23S rRNA base pair 2057-2611 determines ketolide susceptibility and fitness cost of the macrolide resistance mutation 2058A-->G.
    Pfister P; Corti N; Hobbie S; Bruell C; Zarivach R; Yonath A; Böttger EC
    Proc Natl Acad Sci U S A; 2005 Apr; 102(14):5180-5. PubMed ID: 15795375
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis and antibacterial activity of novel ketolides with 11,12-sulfur contained aryl alkyl side chains.
    Chen XZ; Xu P; Liu L; Zheng D; Lei PS
    Eur J Med Chem; 2011 Jan; 46(1):208-17. PubMed ID: 21130543
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.